NO20080951L - Farmasoytisk blanding for behandling av kardiovaskulaere lidelser - Google Patents
Farmasoytisk blanding for behandling av kardiovaskulaere lidelserInfo
- Publication number
- NO20080951L NO20080951L NO20080951A NO20080951A NO20080951L NO 20080951 L NO20080951 L NO 20080951L NO 20080951 A NO20080951 A NO 20080951A NO 20080951 A NO20080951 A NO 20080951A NO 20080951 L NO20080951 L NO 20080951L
- Authority
- NO
- Norway
- Prior art keywords
- immunotherapy
- treatment
- pharmaceutical composition
- cardiovascular disorders
- oxidized ldl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0012—Lipids; Lipoproteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anvendelse av immunterapi mot oksidert LDL for å indusere regresjon av allerede eksisterende ateroskleroselesjoner i et individ. Immunterapien kan være passiv immunterapi ved bruk av antistoffer som bindes til epitoper til stede på oksidert LDL, eller aktiv immunterapi ved bruk av en vaksineblanding for induksjon av en immunrespons mot epitoper til stede på oksidert LDL.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0517878.5A GB0517878D0 (en) | 2005-09-02 | 2005-09-02 | Immunotherapeutic treatment |
PCT/EP2006/008594 WO2007025781A2 (en) | 2005-09-02 | 2006-09-04 | Immunotherapeutic treatment for inducing the regression of atherosclerotic plaques |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20080951L true NO20080951L (no) | 2008-06-02 |
Family
ID=35220745
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20080951A NO20080951L (no) | 2005-09-02 | 2008-02-25 | Farmasoytisk blanding for behandling av kardiovaskulaere lidelser |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090208503A1 (no) |
EP (2) | EP1928913B1 (no) |
JP (1) | JP2009506995A (no) |
KR (2) | KR20080053483A (no) |
CN (1) | CN101316863A (no) |
AU (1) | AU2006286729A1 (no) |
BR (1) | BRPI0615313A2 (no) |
CA (1) | CA2621017A1 (no) |
GB (1) | GB0517878D0 (no) |
IL (1) | IL189847A (no) |
NO (1) | NO20080951L (no) |
NZ (1) | NZ566237A (no) |
RU (1) | RU2454428C2 (no) |
UA (1) | UA96275C2 (no) |
WO (1) | WO2007025781A2 (no) |
ZA (1) | ZA200801959B (no) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008104194A1 (en) * | 2007-02-28 | 2008-09-04 | Bioinvent International Ab | Oxidized ldl and antibodies thereto for the treatment of atheroscleroti c plaques |
CN101951885A (zh) * | 2007-12-28 | 2011-01-19 | 生物发明国际公司 | 制剂 |
EP2332995A1 (en) * | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
JP2014516913A (ja) * | 2010-11-12 | 2014-07-17 | シーダース シナイ メディカル センター | 高血圧の治療及び/又は予防のための免疫調節方法及びシステム |
EP2592423A1 (en) * | 2011-11-08 | 2013-05-15 | Zora Biosciences OY | Lipidomic biomarkers for the prediction of cardiovascular outcomes in coronary artery disease patients not undergoing statin treatment |
US10858422B2 (en) | 2016-05-31 | 2020-12-08 | Abcentra, Llc | Methods for treating systemic lupus erythematosus with an anti-apolipoprotein B antibody |
US20210060071A1 (en) * | 2018-04-27 | 2021-03-04 | The Trustees Of The University Of Pennsylvania | Chimeric Antigen Receptor T Regulatory Cells for the Treatment of Atherosclerosis |
WO2019215300A1 (en) | 2018-05-09 | 2019-11-14 | Medirista Biotechnologies Ab | Antibodies for use in combination therapy |
WO2019232081A1 (en) * | 2018-05-29 | 2019-12-05 | Abcentra, Llc | Compositions and methods for treatment of rheumatoid arthritis and accelerated atherosclerosis |
CA3105071A1 (en) * | 2018-07-02 | 2020-01-09 | Abcentra, Llc | Compositions and methods for reduction of lipoprotein a formation and treatment of aortic valve sclerosis and aortic stenosis |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
GB9701425D0 (en) | 1997-01-24 | 1997-03-12 | Bioinvent Int Ab | A method for in vitro molecular evolution of protein function |
US20030157567A1 (en) * | 1999-09-20 | 2003-08-21 | Joe Lunec | Oxidised fragments of apolipoprotein B and their use |
US6716410B1 (en) | 1999-10-26 | 2004-04-06 | The Regents Of The University Of California | Reagents and methods for diagnosing, imaging and treating atherosclerotic disease |
AU2001233277B2 (en) * | 2000-02-03 | 2004-06-03 | Millennium Pharmaceuticals, Inc. | Humanized anti-ccr2 antibodies and methods of use therefor |
DE10059930A1 (de) * | 2000-11-23 | 2002-05-29 | Fischer Peter | Mittel humanen Ursprungs zur Vakzination gegen GD2-pos. Tumore |
SE0103754L (sv) | 2001-04-05 | 2002-10-06 | Forskarpatent I Syd Ab | Peptider från apolipoprotein B, användning därav immunisering, diagnosmetod eller terapeutisk behandling av ischemiska kardiovaskulära sjukdomar, samt farmaceutisk komposition och vaccin innehållande sådan peptid |
US20030105003A1 (en) * | 2001-04-05 | 2003-06-05 | Jan Nilsson | Peptide-based immunization therapy for treatment of atherosclerosis and development of peptide-based assay for determination of immune responses against oxidized low density lipoprotein |
DE10123074A1 (de) | 2001-05-10 | 2002-11-14 | Monforts Textilmaschinen Gmbh | Vorrichtung zur Wärmebehandlung einer Warenbahn |
SE0302312D0 (sv) * | 2002-10-04 | 2003-08-27 | Forskarpatent I Syd Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
AU2003267905B2 (en) | 2002-10-04 | 2009-02-05 | Biolnvent International Ab | Peptide-based passive immunization therapy for treatment of atherosclerosis |
-
2005
- 2005-09-02 GB GBGB0517878.5A patent/GB0517878D0/en not_active Ceased
-
2006
- 2006-09-04 BR BRPI0615313-5A patent/BRPI0615313A2/pt not_active IP Right Cessation
- 2006-09-04 CA CA002621017A patent/CA2621017A1/en not_active Abandoned
- 2006-09-04 JP JP2008528431A patent/JP2009506995A/ja active Pending
- 2006-09-04 EP EP06777156.8A patent/EP1928913B1/en active Active
- 2006-09-04 RU RU2008112664/10A patent/RU2454428C2/ru not_active IP Right Cessation
- 2006-09-04 WO PCT/EP2006/008594 patent/WO2007025781A2/en active Application Filing
- 2006-09-04 EP EP10075572A patent/EP2319868A1/en not_active Withdrawn
- 2006-09-04 KR KR1020087007952A patent/KR20080053483A/ko active IP Right Grant
- 2006-09-04 CN CNA2006800400065A patent/CN101316863A/zh active Pending
- 2006-09-04 KR KR1020127015596A patent/KR20120101074A/ko active IP Right Grant
- 2006-09-04 UA UAA200804022A patent/UA96275C2/ru unknown
- 2006-09-04 AU AU2006286729A patent/AU2006286729A1/en not_active Abandoned
- 2006-09-04 NZ NZ566237A patent/NZ566237A/en not_active IP Right Cessation
- 2006-09-04 US US12/065,413 patent/US20090208503A1/en not_active Abandoned
-
2008
- 2008-02-25 NO NO20080951A patent/NO20080951L/no not_active Application Discontinuation
- 2008-02-28 IL IL189847A patent/IL189847A/en not_active IP Right Cessation
- 2008-02-29 ZA ZA200801959A patent/ZA200801959B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
CN101316863A (zh) | 2008-12-03 |
EP1928913A2 (en) | 2008-06-11 |
RU2454428C2 (ru) | 2012-06-27 |
AU2006286729A1 (en) | 2007-03-08 |
WO2007025781A3 (en) | 2007-05-03 |
BRPI0615313A2 (pt) | 2012-12-04 |
GB0517878D0 (en) | 2005-10-12 |
US20090208503A1 (en) | 2009-08-20 |
UA96275C2 (ru) | 2011-10-25 |
IL189847A (en) | 2012-02-29 |
WO2007025781A2 (en) | 2007-03-08 |
KR20120101074A (ko) | 2012-09-12 |
RU2008112664A (ru) | 2009-10-10 |
ZA200801959B (en) | 2009-08-26 |
CA2621017A1 (en) | 2007-03-08 |
EP1928913B1 (en) | 2013-06-26 |
KR20080053483A (ko) | 2008-06-13 |
IL189847A0 (en) | 2008-11-03 |
EP2319868A1 (en) | 2011-05-11 |
NZ566237A (en) | 2011-07-29 |
JP2009506995A (ja) | 2009-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20080951L (no) | Farmasoytisk blanding for behandling av kardiovaskulaere lidelser | |
NO20080302L (no) | Humane anti-B7RP1 noytraliserende antistoffer | |
CL2016001254A1 (es) | Mólecula unión cd3 capaz de unirse a cd3 humanos y no humanos (divisional de sol. 3329-13). | |
EA201170381A1 (ru) | Получение сквалена из гиперпродуцирующих дрожжей | |
CO2018000104A2 (es) | Moléculas de anticuerpo que se unen a cd22 | |
HRP20192295T1 (hr) | Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi) | |
DOP2013000029A (es) | Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos | |
MA40041B1 (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
WO2010010466A3 (en) | Neutralizing anti-influenza a virus antibodies and uses thereof | |
PE20140825A1 (es) | Anticuerpos contra il-6 y sus usos | |
AU2010217100A8 (en) | Anti-CepsilonmX antibodies capable of binding to human mIgE on B lymphocytes | |
BR112018000632A8 (pt) | Moléculas de anticorpo que ligam a cd79 | |
EA201071291A2 (ru) | Nmda рецепторные антагонисты для лечения нейропсихиатрических расстройств | |
NO20072253L (no) | Forbedrede vaksiner | |
WO2006072888A3 (en) | Continuous administration of epitopes derived from protein present in atherosclerotic plaque for the treatment of atherosclerosis | |
BR112015001874A2 (pt) | sais e formas sólidas de (s) -3- (4 - ((4-morfolinometil) benzil) oxi) -1-oxoisoindolin-2-il) -piperidina-2,6-diona e composições que compreendem e métodos de utilização das mesmas | |
JP2013540292A5 (no) | ||
CO6210756A2 (es) | La proteina linfopoyetina estromal timica canina y usos de la misma | |
AR065312A1 (es) | Nuevos anticuerpos | |
WO2008043052A3 (en) | Human antibodies neutralizing human metapneumovirus | |
WO2012047267A3 (en) | Polyvalent immunogen | |
UA89780C2 (ru) | Способ лечения или облегчения симптомов атеросклероза с помощью анти-cd3 антитела | |
CL2008000096A1 (es) | Combinacion farmaceutica que comprende dos compuestos uv-absorventes derivados de heptaazafenaleno; y su uso para tratar querotosis actinica, dermatitis, cronica, fotoenvejecimiento, urticaria solar, entre otras. | |
WO2014165028A8 (en) | Antibodies specific to a novel epitope on cemx of human membrane-bound ige and uses thereof in treating ige-mediated diseases | |
EA201200538A1 (ru) | Арабиногалактан для повышения приобретенного иммунного ответа |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |